Navigation Links
Annals of Internal Medicine tip sheet for Feb. 5, 2008, issue
Date:2/4/2008

1. No Clear Winner in Comparative Review of Effectiveness and Harms of Treatments for Localized Prostate Cancer

About 197,000 men will be diagnosed with clinically localized prostate cancer (cancer confined to the prostate gland) in 2008. Common treatments include watchful waiting, surgery to remove the prostate gland, radiotherapy, and androgen deprivation.

A review of these treatments concluded, Accurately assessing comparative effectiveness and harms of localized prostate cancer treatments is difficult due to limitations in the evidence. All treatments result in adverse events, primarily to urinary, bowel and sexual function, that occur soon after therapy, though the frequency, duration and severity may vary between treatments.

Note: This systematic review is being released early online at the Web site of Annals of Internal Medicine www.annals.org. It will appear in the March 18, 2008, print edition of the journal.


2. Gene Expression Tests for Breast Cancer Are Promising But Limited

A review of three commercial gene expression-based prognostic breast cancer tests finds they have potential for improving prognostic and therapeutic prediction, but more data are needed about the amount of improvement, which women will benefit, and how to use the test in decision making about current breast cancer treatment.

Note: This systematic review is being released early online at the Web site of Annals of Internal Medicine www.annals.org. It will appear in the March 18, 2008, print edition of the journal.


3. New Study Refines Thinking on Best Time to Begin HIV Treatment

Debate about the optimal time to begin HIV treatment continues, partly because current mathematical models that weigh harms and benefits over long horizons do not consider drug toxicity and side effects and accrual of HIV drug resistance mutations, which are the primary risks of initiating therapy early.

A new computer simulation incorporates toxicity and side effects of combination antiretroviral therapy (Article, p. 178). It suggests that initiation of combination antiretroviral therapy when the CD4 count falls below 500 cells/mm may increase the life expectancy and quality-adjusted life expectancy of younger patients, particularly if they have higher viral loads.

The simulation also strengthens the case for treating patients with CD4 counts between 200 and 350 cells/mm compared with current guidelines.


4. Expert Group: Do Not Screen Pregnant Women for Bacterial Vaginosis

Bacterial vaginosis is the most common lower genital tract syndrome among women of reproductive age and has been associated with premature births or low birthweight. Because bacterial vaginosis is easy to screen for and treat, some favor screening all pregnant women for it.

But the U.S. Preventive Services Task Force (USPSTF) recommends against screening low-risk women for bacterial vaginosis because there is good evidence that treating the syndrome does not benefit pregnant women at low risk for premature delivery (Clinical Guidelines, p. 214; Update Review, p. 220).

The task force finds insufficient evidence to recommend either for or against screening for the syndrome in pregnant women at high risk for premature delivery.


'/>"/>

Contact: Susan Anderson
sanderson@acponline.org
215-351-2653
American College of Physicians
Source:Eurekalert

Related medicine news :

1. Annals of Internal Medicine tip sheet for Aug. 21, 2007, issue
2. September/October 2007 Annals of Family Medicine tip sheet
3. Annals of Internal Medicine tip sheet for Oct. 2
4. Annals of Internal Medicine Tip Sheet for Nov. 20, 2007, Issue
5. Annals of Internal Medicine tip sheet for Jan. 1, 2008, issue
6. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
7. Internal medicine physicians recommend key elements to guide state initiatives
8. Internal radiotherapy better than external for quality of life in endometrial cancer patients
9. Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Managements Internal Control Review Efforts and on Legal Proceedings
10. Michigan Catholic Conference Launches Massive Internal Stem Cell Education Program
11. Barta joins Conseco as Senior Vice President, Financial Planning & Analysis; Barra named Senior Vice President, Internal Audit; Clarke to head Investor Relations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The Association for Medical ... Jan Fox will serve as keynote speaker at the organization’s 2016 Spring Conference. ... to more effectively communicate with their own organizational staff and leadership. , ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... make Everseat digital self-scheduling readily available to physicians. The integration will ... can find and select appointments via Everseat’s free mobile app. , The partnership ...
(Date:2/10/2016)... ... February 10, 2016 , ... The recreational use of marijuana has been legal ... face a lot of restrictions as to where they can smoke pot. , ... and that cannabis “may not be consumed openly or publicly.” , Given the momentum ...
(Date:2/10/2016)... ... February 09, 2016 , ... According to a recent ... dramatic increase in the number of patients under the age of 30. According to ... seeing in their offices, and may indicate an overall shift in the rapidly growing ...
(Date:2/9/2016)... ... February 09, 2016 , ... Interstate Restoration LLC, a full ... today the acquisition of Hawaii DKI. Hawaii DKI is one of the more ... companies who excel at service and response helps support our goal of becoming ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)...  Visage Imaging Inc. ("Visage"), a wholly owned ... that the American College of Radiology (ACR) and ... Visage 7 Enterprise Imaging Platform as the new ... SIMulation (SIM). SIM is the assessment component of ... multi-faceted and fully-integrated online assessment, education and remediation ...
(Date:2/10/2016)... -- CERS ), Medivation, Inc. (NASDAQ: MDVN ... Therapeutics, Inc. (NASDAQ: CLDX ). --> CERS ... (NASDAQ: ADMS ) and Celldex Therapeutics, Inc. (NASDAQ: ... become vitally important in the development of targeted treatment therapies ... which are defined as those intended for the safe and ...
(Date:2/10/2016)... Israel , February 10, 2016 /PRNewswire/ ... leader in the field of cartilage repair, announces the ... 5, 2016. The $15 million investment was led by ... pharmaceutical manufacturer, and was joined by existing Regentis investors ... and both the Technion Research & Development Foundation and ...
Breaking Medicine Technology: